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Context: Anti-Müllerian hormone (AMH) is produced by the granulosa cells (GCs) of growing
follicles and inhibits follicular development.
Objective: This study aimed to investigate the regulation of the AMH-specific receptor gene
(AMHR2) expression in GCs by bone morphogenetic protein 15 (BMP15), BMP4 and growth dif-
ferentiation factor 9 (GDF9).
Design, Setting, Patients: Their effects on AMHR2 and AMH mRNAs were studied in luteinized
humanGCs (hGCs) and inovineGCs (oGCs) fromsmall antral follicles. Theeffects ofBMPsonhuman
AMHR2andAMHpromoter reporteractivitieswereanalyzed in transfectedoGCs. The in vivoeffect
of BMP15 on GCs AMHR2 and AMH expression was investigated by using Lacaune and Rasa Ara-
gonesa hyperprolific ewes carrying loss-of-function mutations in BMP15.
Main Outcome Measures: mRNAs were quantified by real-time RT-PCR. Promoter reporter con-
structs activities were quantified by the measurement of their luciferase activity.
Results: BMP15 and BMP4 enhanced AMHR2 and AMH expression in hGCs and in oGCs whereas
GDF9 had no effect. In oGCs, GDF9 increased BMP15 effect on AMH expression. Consistent with
these results, BMP15 and BMP4, but not GDF9, enhanced AMHR2 promoter activity in oGCs,
whereas GDF9 increased BMP15 effect on AMH promoter activity. Moreover, oGCs from both
BMP15mutant ewes had reducedAMHR2mRNA levels but unchangedAMH expression compared
to wild-type ewes.
Conclusions:Altogether, these results suggest that themechanisms of action of BMP15 onAMHR2
and AMH expression are different, and that by stimulating AMHR2 and AMH expression in GCs
BMP15 enhances AMH inhibitory actions in GCs.
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Anti-Müllerian hormone (AMH), also called Mülle-rian-inhibiting substance, is a member of the trans-
forming growth factor beta (TGFß) familywell known for
its role on Müllerian duct regression during male sexual
differentiation (1). In females, AMH is expressed in the
granulosa cells (GCs) of growing follicles and it impor-
tantly modulates follicle growth and maturation, partic-
ularly by inhibiting the FSH sensitivity of follicles (2). Se-
rum AMH is increasingly used in clinical practice as an
early indicator of GCs tumors (3), as well as a reliable
marker of ovarian reserve and of ovarian response to go-
nadotropin-based stimulatory treatments (4). The expres-
sion of AMH starts in primary follicles, is the highest in
small antral ones and then decreases as follicles grow, ex-
cept in cumulus cells surrounding the oocytes (5). In rat (6)
and rabbit (7) ovaries, the AMH-specific type II receptor
AMHR2 is coexpressed with AMH in GCs from growing
preantral and small antral follicles. In human preovula-
tory follicles, both AMH and AMHR2 mRNAs are more
expressed in cumulus cells than in mural GCs (8). How-
ever, the factors involved in the expression pattern of
AMH and AMHR2 in GCs are still poorly documented.
The bone morphogenetic proteins (BMPs) are cyto-
kines also belonging to the TGFß family, and over 20
BMPs have been identified up to now. BMPs contribute to
the regulation of cellular proliferation, differentiation and
apoptosis in a variety of tissues, including the ovary in
which they are important regulators of folliculogenesis.
Particularly, BMP15 and GDF9, known to be specifically
expressed in the oocyte (9, 10) and acting alone or in syn-
ergy, are key regulators of follicle development, ovulation
rate and oocyte quality (11–14). BMP4 is detected in gran-
ulosa and/or theca follicular cells depending upon species
(15) and it modulates gonadotropin-induced steroidogen-
esis (16, 17). BMP15 and BMP4 activate SMAD1/5/8 sig-
naling pathwaywhereas GDF9 and activin signal through
SMAD2/3 proteins (18, 19). Recently, several BMPs have
been shown to enhanceAMH expression in GCs (20–24),
but their effect on AMHR2 expression is unknown.
The aim of this work was to test whether BMPs could
regulate AMHR2 expression and its promoter activity.
The effects of oocyte-derived BMP15 and GDF9 were
compared with those of granulosa/theca cells-derived
BMP4, a canonical inducer of theBMPsignaling pathway.
The regulation ofAMHR2mRNAswas studied in vitro in
two models of primary GCs at different stages of their
differentiation: human granulosa-luteal cells (hGCs) from
women undergoing assisted reproduction technology
(ART) procedures and ovine GCs (oGCs) from small an-
tral follicles. Themechanismof BMP15,GDF9andBMP4
action on AMHR2 promoter was addressed in oGCs. In
addition, we analyzed the in vivo effect on GCs AMHR2
expression of two natural loss-of-function mutations of
BMP15 carried by Lacaune and Rasa Aragonesa ewes,
which cause hyperprolificacy when present at the
heterozygous state and sterility when present at the ho-
mozygous state (25, 26).
Materials and Methods
Subjects
Twenty-nine patients aged 24–38 years undergoing ART
were included in this study according to the following inclusion
criteria: 1) both ovaries present, with no morphological abnor-
malities at transvaginal ultrasound; 2) menstrual cycle length
range between 25 and 35 days; 3) no current or past diseases
affecting ovaries or gonadotropin or sex steroid secretion, clear-
ance, or excretion; 4) no clinical signs of hyperandrogenism; 5)
body mass indexes ranging between 18 and 25 kg/m2, and 6)
inclusion in a standard long GnRH agonist suppression proto-
col. An informed consentwas obtained fromall women, and this
investigation received the approval of our internal institutional
review board (IRB).
Collection and culture of human granulosa-luteal
cells
After oocyte isolation, follicular fluids fromeachpatientwere
centrifuged as described (27) through a Percoll gradient at 350 g
for 15 minutes. Human GCs were collected at the interface and
seeded at 3  105 cells per well in 6-well plates in Dulbecco’s
modified Eagle’s medium/F-12 containing 10% fetal calf serum,
100 U/ml penicillin and 100 g/ml streptomycin (all products
from Invitrogen, Carlsbad, CA). The next day, hGCs were
treated for 48 hours in serum-free conditions with or without 10
ng/ml of recombinant human (rh) BMP4, BMP15 and/or GDF9
(R&D Systems Europe, Lille, France).
Animals
For cultures of oGCs, ovaries were recovered from ewes of
various breeds during the period of seasonal reproduction after
slaughtering in a local slaughterhouse at Nouzilly (France). For
in vivo AMHR2 expression studies, ovaries from all genotypes
were recovered in the follicular phase of the cycle as described
(20), after slaughtering of the ewes atZaragoza (Spain) andTou-
louse (France), for the Rasa Aragonesa and Lacaune breeds, re-
spectively.All procedureswere approvedby theAgricultural and
Scientific Research Government Committees and local ethical
committees (Approval numbers C37–175-2 in Nouzilly, C31–
429-01 in Toulouse and ES 50 297 0012 005 in Zaragoza) in
accordance with the guidelines for Care and Use of Agricultural
Animals in Agricultural Research and Teaching.
Collection and culture of ovine granulosa cells
Collected ovaries were finely dissected to isolate all the antral
follicles larger than 1 mm in diameter. For each animal, the fol-
licles were then classified according to their size and genotype
when useful and oGCs were recovered as described (20).
For culture experiments, oGCs from 1–3 mm follicles were
cultured for 48 hours in serum-free conditions (20) with and
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without rh BMP4, human BMP15, mouse GDF9 or human/
mouse/rat Activin A (50 ng/ml each; R&D System Europe).
For the evaluation of in vivo AMHR2 and AMH expression,
three follicular classes were defined (1–3 mm; 3–5 mm;5mm)
corresponding to follicle growth, selection and dominance
stages, respectively. Then oGC pools of each follicle size-class
were established per animal.
Western blotting analysis
Twenty-four hours after seeding, for hGCs, and immediately
after collection, for oGCs, cells were serum starved, treated 1
hour with human BMP4, BMP15, GDF9, both BMP15 and
GDF9, or Activin A (10 ng/ml or 50 ng/ml each for hGCs and
oGCs respectively) and lysates were prepared as described (27).
Thirty g were subjected to SDS-PAGE (Bio-Rad, Marnes-la-
Coquette, France), then blots were successively incubated with
antibodies against phospho-SMAD/1/5/8, phospho-SMAD/2/3
(Cell Signaling Technology, Ozyme, Montigny-le-Bretonneux,
France) both at 1:1000, and Actin (Sigma, L’Isle d’Abeau
Chesnes, France). Then membranes were probed with peroxi-
dase-labeled antibodies (1:5000) and the bands were visualized
with the ECL Plus detection reagent (Pierce, ThermoFischer Sci-
entific, Villebon-sur-Yvette, France).
RNA extraction and quantitative real-time PCR
Total RNAs were extracted from hGCs using the RNA Plus
extraction kit (Qiagen, Courtaboeuf, France) and from oGCs
using the Nucleospin RNA II kit (Macherey-Nagel, Hoerdt,
France). Reverse transcription was performed with the Omnis-
cript Reverse Transcription Kit (Qiagen) using 1 g RNA.
Quantification of AMHR2, AMH, STAR (Steroidogenic
Acute Regulatory protein), CYP19A1 (Cytochrome P450, Fam-
ily 19, Subfamily A, Polypeptide 1/Aromatase) and RPL19 (Ri-
bosomal Protein L19) mRNAs in hGCs was performed by real-
time PCR using the TaqMan PCR method (Roche Diagnostics,
Meylan, France) as described (27) with the primers and probes
shown in Supplemental Table 1. For oGCs, AMHR2, AMH,
SMAD6, CYP11A1 (Cytochrome P450, Family 11, Subfamily
A, Polypeptide 1/P450 side chain cleavage enzyme) and RPL19
mRNAswere quantified using SYBRGreen Supermix on an iCy-
cler iQ multicolor detection system (Bio-Rad) as previously de-
scribed (28) with the primers shown in Supplemental Table 1.
The cycle threshold (Ct) of the target gene was compared with
that of theRPL19 internal reference (Ref) gene, according to the
ratio R  [ERef
Ct (Ref)/Etarget
Ct (target)].
Gene constructs, targeted mutagenesis and
transient transfection studies
A 2252 (-2197,54) base pairs (bp) human AMHR2 pro-
moter (RefSeqGene NG_015981) reporter construct
(2252_AMHR2-luc)was prepared by cloning successively a 428
bp (-374,54) fragment anda1825bpdistal promoter fragment
(-2199,-374) into the BglII and HindIII sites of the pGL2-Basic
vector.
Ovine GCs were seeded in 24-well plates and reporter gene
constructs (750 ng/well) were transfected into oGCs for 6 hours
using Lipofectamine PLUS transfection reagent (ThermoFisher
Scientific) as described (20). After transfection, cells were cul-
tured for 24 hours in serum-free conditions with or without rh
BMP4 (50 ng/ml), human BMP15 (100 ng/ml), mouse GDF9
(100 ng/ml) or a combination of BMP15 and GDF9 before lu-
ciferase assay (Luciferase Assay System, Promega, Charbon-
nières, France).
AMHR2 immunohistochemistry
Two ovaries of each genotype were recovered from Lacaune
and Rasa Aragonesa ewes, fixed in Bouin, embedded in paraffin
and serially sectioned at a thickness of 7m. Immunohistochem-
istry analyses were performed as described (22) using a mouse
monoclonal antibody raised against human AMHR2 (antibody
12G4, 1/200, (29).
Statistics
All datawere analyzed using the Prism6 Software (GraphPad
Software Inc., La Jolla, CA, USA) and the tests mentioned in the
figure legends. Results are presented as mean  SEM.
Results
AMHR2 expression is increased by BMP4 and
BMP15 in human GCs
The regulation of AMHR2 expression by BMP4,
BMP15 and GDF9 was analyzed in hGCs obtained from
women undergoing ART. First, we checked the ability of
these cells to respond to BMP family members. As ex-
pected, BMP4 or BMP15 induced the phosphorylation of
theSMAD1/5/8 signalingproteinswhereasGDF9 induced
that of SMAD2/3, the combination of BMP15 and GDF9
activating both signaling pathways (Figure 1A). Then, we
tested the effects of a 48 hours treatment by BMPs on the
expression of some of their known target genes and of
AMHR2 in hGCs (Figure 1B, C, D, E). BMP4 inhibited
STAR expression, had no effect on CYP19A1 and en-
hanced AMH mRNA levels. BMP15 inhibited STAR ex-
pression whereas it up-regulated CYP19A1 and AMH
mRNA levels. GDF9 decreased CYP19A1 expression but
had no effect on STAR and AMH mRNAs levels. The
combination of BMP15 and GDF9 induced a more pro-
nounced decrease in STAR and CYP19A1 mRNA levels
than did BMP15 or GDF9 alone, but had the same effect
as BMP15 onAMH expression. InterestinglyAMHR2 ex-
pression was stimulated by both BMP4 and BMP15,
whereas GDF9 alone or in combination with BMP15 had
no effect (Figure 1E).
AMHR2 expression is increased by BMP4 and
BMP15 in ovine GCs
We then studied the regulation of AMHR2 expression
in oGCs from small antral growing follicles, which highly
express AMH. Here again, we first checked the ability of
the cells to respond to BMP familymembers.We also used
Activin A, another member of the TGFß family known to
activate the same SMAD2/3 signaling pathway as GDF9
(30). As expected, BMP4 or BMP15 induced the phos-
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phorylation of the SMAD1/5/8 signaling proteinswhereas
GDF9 and Activin A induced that of SMAD2/3, the com-
bination of BMP15 and GDF9 activating both signaling
pathways (Figure 2A). Then, we tested the effects of a 48
hours treatment by BMPs andActivin A on the expression
of some of their known target genes and of AMHR2 in
oGCs (Figure 2B, C, D, E). SMAD6 and CYP11A1 were
chosen as BMP-target genes in oGCs instead of STAR and
CYP19A1 because at this stage of differentiation these
latter genes are poorly expressed by oGCs. BMP4 en-
hanced SMAD6, CYP11A1 and AMH expression in
oGCs. BMP15 also up-regulated SMAD6, CYP11A1 and
AMH mRNA levels. GDF9 alone down-regulated
CYP11A1 expression and had no effect on SMAD6 and
Figure 1. Effect of BMP4, BMP15 and GDF9 on human granulosa cells (hGCs). (A) Western blotting analysis of SMAD phosphorylation in hGCs,
after one hour stimulation in control medium or with 10 ng/ml of human BMP4, BMP15, GDF9, or BMP15  GDF9 (10 ng/ml each). Actin
detection was used as gel loading control. (B, C, D, E) Expression of STAR, CYP19A1, AMH and AMHR2 in hGCs after 48 hours of culture in
control medium (Ctrl, cells cultured without ligand) or with human BMP4 (10 ng/ml), BMP15 (10 ng/ml), GDF9 (10 ng/ml) or BMP15  GDF9 (10
ng/ml each). Messenger RNA accumulation of STAR (B), CYP19A1 (C), AMH (D), AMHR2 (E) was studied by reverse transcription and quantitative
PCR relatively to RPL19 as internal reference. The results were expressed in percentage of expression relatively to that of cells cultured without
ligand (Ctrl, fixed at 100%). n represents the number of women. Because the small number of cells did not allow us to apply all the different
treatments in the same experiment, data were analyzed using the Wilcoxon matched pairs test; *, P  .05; **, P  .01; ***, P  .001, vs Ctrl or
between BMP15 and BMP15GDF9 conditions (black bar) or between GDF9 and BMP15GDF9 conditions (black bar).
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AMH mRNA levels. The combination of BMP15 and
GDF9 slightly reduced BMP15 effects on SMAD6 and
CYP11A1 expression, but enhanced its stimulating effect
on AMH expression. Activin A inhibited SMAD6 and
CYP11A1 expression and up-regulatedAMHmRNA lev-
els. Like in hGCs, AMHR2 expression was enhanced by
BMP4 or BMP15 in oGCs (Figure 2D). GDF9 andActivin
A had no effect. The combination of BMP15 and GDF9
had a stimulatory effect comparable to that obtainedwith
BMP15alone. Similar resultswereobtainedwith rhGDF9
instead of murine GDF9 (data not shown).
Figure 2. Effect of BMP4, BMP15, GDF9 and Activin A on ovine granulosa cells (oGCs). (A) Western blotting analysis of SMAD phosphorylation
in oGCs from 1 to 3 mm follicles, after one hour stimulation in control medium or with 50 ng/ml of human BMP4, BMP15, GDF9, BMP15  GDF9
(50 ng/ml each) or Activin A (ActA). Actin detection was used as gel loading control. (B, C, D, E) oGCs were cultured in 96-well plates for 48 hours
with or without 50 ng/ml of the different factors. Each treatment was tested in 12 replicate wells, then cells were pooled according to treatment
at the end of culture for mRNA preparation. Messenger RNA accumulation of SMAD6 (B), CYP11A1 (C), AMH (D) and AMHR2 (E) was studied by
reverse transcription and quantitative PCR relatively to RPL19 as internal reference. The results were expressed in percentage of expression
relatively to that of cells cultured without ligand (Ctrl, fixed at 100%). Data represent the results of 10 independent experiments performed for
each treatment. Comparisons of means between different treatments were made by repeated measures one-way ANOVA with the Greenhouse-
Geisser correction, followed by Fisher’s LSD test for multiple comparisons.*: P  .05, **: P  .01, ***: P  .001, vs. Ctrl or between BMP15 and
BMP15GDF9 conditions (black bar).
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BMP4 and BMP15 stimulate the activity of a
human AMHR2 promoter construct
We next tested whether BMP4, BMP15 and GDF9
could regulate the human AMHR2 gene promoter activ-
ity. Primary cultures of oGCs were transfected with the
2252_AMHR2-luc construct or a humanAMH proximal
promoter construct (423_AMH-luc) used as a control of
the BMP responsiveness of the transfected oGCs (20). The
activity of the 423_AMH-luc construct was stimulated by
BMP4 as previously shown (20), but also by BMP15 and
the combination of BMP15 andGDF9, GDF9 alone being
ineffective (Figure 3A). The combination of BMP15 and
GDF9 slightly enhanced BMP15 effects on 423_AMH-luc
activity. BMP4 and BMP15 increased 2252_AMHR2-luc
activity (Figure 3B); GDF9 had no effect on this construct
and the effect of the combination of BMP15 and GDF9
was similar to the effect of BMP15 alone. Potential
SMAD-binding elements (SBEs) and BMP-response ele-
ments (BRE) (31) on the 2252 bp human AMHR2 pro-
moter are indicated in Figure 3C.
AMHR2 expression is reduced in
two models of ewes carrying
natural mutations in the BMP15
gene
Finally, we took advantage of
sheepmodels carrying natural muta-
tions in theBMP15 gene to study the
in vivo effect of BMP15 on AMHR2
expression in growing follicles. We
analyzed the differential expression
level of AMHR2 and AMH mRNA
in GCs from Lacaune and Rasa Ara-
gonesa ewes either noncarriers or
heterozygous carriers of the FecXL
or the FecXR mutations, respec-
tively. The FecXL mutation is a
C321Y missense non conservative
substitution of a cysteine to a ty-
rosine in the mature peptide of the
protein,which leads to a defect in the
protein secretion (26). The FecXR
mutation is a 17 bp deletion which
creates apremature stopcodon in the
proregion (25). Both mutations lead
to a total loss of BMP15 function
(25, 26). In both breeds, AMH mR-
NAs levels in mutant ewes were not
significantly different from those ob-
tained for wild-type animals in all
categories of antral follicles (Figure
4A, C). In contrast,AMHR2 expres-
sion was dramatically reduced in
GCs from 3–5mm and 5mm in FecXL-carrier Lacaune
and 3–5 mm in FecXR-carrier Rasa Aragonesa antral fol-
licles when compared towild-type follicles (Figure 4B, D).
In keeping with these results, AMHR2 immunostaining
was lower in GCs of mutant ewes than in wild-type ones
(Figure 4E, F and Supplemental Figure 1).
Discussion
In this work, we showed that BMP15 and BMP4 signifi-
cantly enhanced AMHR2 mRNA levels in hGCs and in
oGCs,whereasGDF9acting alone or in combinationwith
BMP15 had no effect. In oGCs, BMP15 and BMP4 en-
hanced alsoAMHmRNA levels, and GDF9 increased the
stimulating effect of BMP15. In keepingwith these results,
BMP15 and BMP4, but not GDF9, enhanced AMHR2
promoter activity in oGCs, whereas GDF9 increased the
stimulating effect of BMP15 on AMH promoter activity.
Moreover, oGCs from hyperprolific ewes, carrying loss-
Figure 3. Effect of BMP4, BMP15 and GDF9 on AMH and AMHR2 promoter activities in oGCs.
(A, B) Granulosa cells recovered from 1 to 3 mm ovine follicles were seeded in 24-well plates at
250 000 cells/well, then they were transfected with (A) an AMH reporter gene construct
(consisting of 423 bp from the human AMH promoter) or (B) with an AMHR2 reporter gene
construct (consisting of 2252 bp from the human AMHR2 promoter). Both promoter fragments
were inserted upstream of the luciferase reporter gene. After transfection, oGCs were cultured
for 24 hours in control medium (Ctrl, cells cultured without ligand) or with human BMP4 (50 ng/
ml), human BMP15 (100 ng/ml), mouse GDF9 (100 ng/ml) or BMP15GDF9 (100 ng/ml each).
Each treatment was tested in triplicate. Results represent the mean of six independent
experiments and are expressed as a percentage of activity relatively to that of cells cultured
without ligand (Ctrl, fixed at 100%). Data were analyzed using two-way ANOVA (in order to
estimate the treatment and the culture effect), followed by Fisher’s LSD test for multiple
comparisons. *: P  .05, **: P  .01, ***: P  .001, vs. Ctrl or between BMP15 and
BMP15GDF9 conditions (black bar). C, Potential SBE and BRE on the human AMHR2 promoter
(relative to 1 transcription start site).
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Figure 4. Consequence of the presence of natural loss-of-function mutations in the BMP15 gene on AMH and AMHR2 expression in oGCs from
sheep growing follicles. (A, B, C, D) For each ewe, follicles recovered after ovarian dissection were allocated to 3 size classes (1–3 mm, 3–5 mm,
and  5 mm). In panels A to D, results represent AMH and AMHR2 mRNA expression in granulosa cells recovered from /FecXL (n  5) and /
(n  7) Lacaune ewes (A and B), and /FecXR (n  6) and / (n  6) Rasa Aragonesa ewes (C and D). AMH (A and C) and AMHR2 (B and D)
mRNA accumulation was studied by reverse transcription and quantitative PCR and represented as mRNA relative level, using RPL19 as an internal
reference. Data were analyzed by one-way ANOVA. Different letters indicate significant differences (P  .05) between follicular classes and
genotypes. (E, F) Photomicrographs of ovarian sections from wild-type (/) and mutant /FecXL and /FecXR ewes, after immunostaining with
anti-AMHR2 (12G4) mouse monoclonal antibody. Immunohistochemistry experiment was performed simultaneously on ovarian sections from /
and mutant ewes. The panel (E) illustrates AMHR2 immunostaining in antral follicles of 4 to 6 mm in diameter present in / (top) and
/FecXL(bottom) Lacaune ovaries. The panel (F) illustrates AMHR2 immunostaining in antral follicles of 3 mm in diameter present in / (top) and
/FecXR (bottom) Rasa Aragonesa ovaries. A Antrum; G  Granulosa cells; O  Oocyte; T  Theca. Scale bar, 100 m.
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of-function mutations in BMP15, had reduced AMHR2
mRNA levels compared to wild-type mono-ovulating an-
imals, but these mutations had no effect on AMH expres-
sion. Altogether, these results indicate that BMP15 up-
regulates bothAMHR2 andAMH expression in GCs, but
do so by different mechanisms (Figure 5A). Remarkably,
BMP15 is efficient on GCs at different stages of their dif-
ferentiation and in different species. It is suggested that
hyperprolificacy in ewes could result from a decrease in
bothBMPandAMHinhibitory actions onGCsduring the
FSH-dependent phase of terminal follicular development
(Figure 5B).
From our results, the effects of BMP15 and BMP4 are
markedly different from those of GDF9 and Activin A.
This is true for AMHR2 but also for the other BMP/Ac-
tivin target geneswe studied. Indeed,
in hGCs, BMP15 stimulates whereas
GDF9 inhibits CYP19A1 expres-
sion, and in oGCs, BMP4 and
BMP15 stimulate CYP11A1 and
SMAD6 expression whereas these
genes are down-regulated by GDF9
and Activin A respectively. These re-
sults are in keeping with a multifac-
torial regulation of genes involved in
folliculogenesis. However, the simi-
larity of BMP4 and BMP15 effects
on one hand, and of GDF9 and Ac-
tivin A effects on the other hand,
could be partly due to the fact that
they activate the same SMAD1/5/8
and SMAD2/3 pathways respec-
tively. The fact that in oGCs, Activin
A mimics the effect of the BMP fac-
tors in up-regulating AMH mRNA
levels, suggests that both SMAD1/
5/8 and SMAD2/3 signaling path-
ways can enhance AMH expression
in oGCs.
The combination of BMP15 and
GDF9 has the same effect than
BMP15 on AMHR2 expression,
confirming that GDF9 is not in-
volved in the regulation of this gene
(Figure 1 and 2). In contrast, BMP15
andGDF9 exert an additive effect on
SMAD6 and CYP11A1 expression
and a synergistic effect on STAR and
CYP19A1 expression. Moreover, a
synergistic effect of BMP15 and
GDF9 is also noticeable onAMH ex-
pression in oGCs. As shown by Peng
et al (32) for genes involved in cu-
mulus expansion, additive or cooperative effects between
these two factors can be explained by the formation of
GDF9/BMP15 heterodimers which are more potent than
each homodimers alone. The lack, in BMP15 and GDF9,
of the seventh cysteine of the Cys-knot domain (which is
present in all other members of the TGFß family (33)),
likely allows them to dimerize noncovalently with each
other. In agreementwith this explanation,Mottershead et
al (33) demonstrated recently that the potent synergistic
actions ofGDF9 andBMP15onGCs does not occurwhen
a covalent form of BMP15, instead of a noncovalent one,
is addedwithGDF9 in the culturemedium. Based on these
data, we can hypothesize that homodimers of BMP15 are
likely necessary to regulate AMHR2 expression whereas
Figure 5. Diagrams illustrating the mechanisms of action of BMP15 and GDF9 on GCs. A,
Interactions between BMP15 and GDF9 to regulate their target genes through the
phosphorylation of SMAD proteins. BMP15 and GDF9 can act as homodimers or highly potent
BMP15/GDF9 heterodimers in granulosa cells (32), with different impacts on the activation of
SMAD1/5/8 and SMAD2/3 pathways and the expression of target genes. B, Working hypothesis
of regulation of folliculogenesis and ovulation rate by BMP15 through AMH and AMHR2. It is
suggested that low BMP15 and low AMH signaling in follicles of ewes carrying a loss-of-function
mutation in BMP15 at the heterozygote state (/m) both contribute to sensitizing granulosa cells
to FSH, thereby enhancing the number of ovulations at each ovarian cycle.
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both homodimers of BMP15 and heterodimers with
GDF9 might modulate AMH mRNA levels (Figure 5A).
In vivo, BMP15 regulates also differently AMH and
AMHR2 expression. Indeed, AMHR2 but not AMH ex-
pression is reduced in the GCs from Lacaune and Rasa
Aragonesa ewes (Figure 4), which carry a loss-of-function
BMP15 mutation at heterozygous state, and which thus
lack one “dose” of BMP15. This means that “two doses”
of BMP15 are necessary for AMHR2 expression whereas
“one dose” is sufficient for that ofAMH. Because BMP15
and BMP4 have a similar stimulatory effect on AMHR2
expression in vitro, the decrease inAMHR2 expression in
GCs from mutant ewes suggests that the factors up-regu-
latingAMHR2mRNA, including BMP4, cannot compen-
sate the lack of effect of BMP15. In contrast, the stimu-
latory effect of Activin A or other factors on AMH
expression could compensate the loss of one copy of
BMP15. Moreover, and as said above, our in vitro results
(Figure 2) suggest that the expression of AMH could also
be supported by the action of BMP15/GDF9heterodimers
with a highly potent stimulatory effect.
The ability of BMP15 andBMP4 to enhance the human
AMHR2 reporter gene activity in ovine GCs (Figure 3)
suggests that they could act on the transcription of this
gene. BMP15 and BMP4 mainly phosphorylate the
SMAD1/5/8 proteins which in turn interact with SMAD4
and translocate to the nucleus. SMAD4 directly binds to
SBE (35) but SMAD1/5/8 onlyweakly bind to this element
and prefer GC-rich elements, often referred to BRE (31).
The presence of several potential SBE and BRE within the
human AMHR2 promoter (Figure 3C) is in keeping with
a direct effect of BMP15 and BMP4 on its transcription
through SMAD factors. In addition, other transcription
factors, such as SOX9, SF1 and GATA4 present in the
AMHR2 promoter, could act in synergy with SMAD pro-
teins. Supporting this hypothesis,AMHR2 transcription is
up-regulated by SF1 and SOX9 in heterologous cells sys-
tems (36). In addition, we have recently found that SF1
binding sites are necessary for BMP4 activation through
SMAD1 of the AMH promoter in ovine GCs (20).
Both BMPs andAMHare known to repress FSHaction
in GCs. Indeed in mice, the knock-out of the AMH gene
leads tomore growing follicles, a higher sensitivity to FSH
treatment and an earlier depletion of the follicle pool (2).
In human, mutations in the BMP15 gene (37) and in the
AMH gene (38) at the heterozygous state have been asso-
ciated with premature ovarian failure or insufficiency. As
suggested by Inagaki et al (39), this could be due to im-
paired levels or decreased activity of mutant proteins,
leading to a short period of enhanced fertility followed by
a rapid exhaustion of the ovarian reserve. In sheep, as
proposedbyFabre et al (40), loss-of-functionmutationsof
BMPsor their receptors at the heterozygous state are likely
responsible for the increase in ovulation rate, the reduced
inhibiting action of BMP on FSH responsiveness promot-
ing the selection and maintenance of follicles during the
follicular phase, when circulating concentration of FSH is
decreasing.The stimulatory effect ofBMP15onAMHand
AMHR2 expression we have demonstrated in the present
study suggests that hyperprolificacy in heterozygous ewes
carrying a loss-of-function BMP15mutation could be due
to the combined decrease of BMP15 and AMH inhibitory
actions on FSH-dependent folliculogenesis (Figure 5B).
In conclusion, in this study,wehave shown thatBMP15
stimulates AMHR2 expression in GCs at different stages
of differentiation both in vitro and in vivo. The ability of
BMP15 to enhance the activity of a human AMHR2 re-
porter gene suggests that it could act on its transcription,
but further experiments are required to define its precise
mechanism of action. The fact that BMP15 and BMP4
stimulate bothAMH andAMHR2 expression suggests an
important role of factors of the BMP family, of somatic or
oocyte origin, in triggeringAMH andAMHR2 expression
in primary follicles and/or in sustaining their expression in
antral ones, thus emphasizing their inhibitory effect on
FSH action on GCs.
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